Discussion
As an advocate for the New Zealand Amyloidosis Patients Association since 2019, I am acutely aware that when there is no center of excellence or coordinated…
Featured Articles
Blood levels of signaling molecules that promote tissue scarring, or fibrosis, are elevated in people with transthyretin amyloid cardiomyopathy (ATTR-CM), and higher levels of these molecules are associated with worse clinical outcomes for ATTR-CM patients, a study found. “Our study highlights the importance of fibrosis-related biomarkers in the [disease…
Discussion
Minimally invasive skin biopsies may be used to diagnose transthyretin amyloidosis and guide treatment in people with the rare progressive disease, according to the findings…
People with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer when the disease is diagnosed and treated earlier, with treatment benefits being much smaller in older…
The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on a Phase 3 clinical trial testing the investigational gene-editing therapy, nexiguran ziclumeran…
More than half of adults with hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM), a condition marked by heart damage, also have multi-nerve damage, according to…
Perspectives
-
Discussion
-
Discussion
-
Discussion
-
Discussion
-
Discussion
-
Discussion
Newly diagnosed? Start your journey here.
Need to know
Becoming educated and informed about FAP is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
Personal experiences
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your FAP journey.
Treatment
There is no cure for FAP yet, but there are treatments that can help manage the disease. Learn more about the approved and experimental therapies here.